Key Developments: Endo International PLC (ENDP.OQ)

ENDP.OQ on NASDAQ Stock Exchange Global Select Market

69.59USD
17 Dec 2014
Price Change (% chg)

$1.86 (+2.75%)
Prev Close
$67.73
Open
$67.91
Day's High
$69.74
Day's Low
$67.64
Volume
731,219
Avg. Vol
747,410
52-wk High
$82.00
52-wk Low
$53.62

Search Stocks

Latest Key Developments (Source: Significant Developments)

Endo International PLC completes acquisition of rights to Natesto Testosterone Nasal Gel
Tuesday, 9 Dec 2014 07:00am EST 

Endo International PLC:Says completion of acquisition of rights to Natesto (testosterone nasal gel), first and only testosterone nasal gel for replacement therapy in adult males diagnosed with hypogonadism, from Trimel BioPharma SRL, wholly-owned subsidiary of Trimel Pharmaceuticals Corp.Says acquisition for $25 mln including additional payments upon achievement of certain regulatory and sales milestones.  Full Article

Endo International PLC acquires rights to Natesto Testosterone Nasal Gel from Trimel Pharmaceuticals Corp's subsidiary
Monday, 24 Nov 2014 07:00am EST 

Endo International PLC:Announced the acquisition of rights to Natesto (testosterone nasal gel), the first and only testosterone nasal gel for replacement therapy in adult males diagnosed with hypogonadism, from Trimel BioPharma SRL, a subsidiary of Trimel Pharmaceuticals Corp.Says under the terms of the agreement Trimel will receive an upfront payment of $25 mln and could receive additional payments upon the achievement of certain regulatory and sales milestones.Says additionally, Trimel will be responsible for the manufacture and supply of Natesto and Endo will pay a tiered supply price for the product.Says it expects the transaction to close in early 2015.Says under the terms of the agreement, Endo receives sole and exclusive commercial rights to the Natesto product in the US and Mexico.Says in addition, Endo will collaborate on all regulatory and clinical development activities in coordination with Trimel.  Full Article

Endo International PLC's subsidiary Launches generic version of Valcyte
Thursday, 20 Nov 2014 07:30am EST 

Endo International PLC:Says a subsidiary has launched a generic version of Hoffmann-La Roche Inc's Valcyte.  Full Article

Endo International PLC announces termination of HSR act waiting period in connection with proposed acquisition of Auxilium Pharmaceuticals Inc
Wednesday, 19 Nov 2014 07:30am EST 

Endo International plc and Auxilium Pharmaceuticals Inc:Says that the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended (HSR Act) in connection with Endo's proposed acquisition of Auxilium was terminated by the United States Federal Trade Commission on Nov. 18.Expects the deal to close in the first quarter of 2015, subject to pending customary closing conditions.Says it would acquire all of the outstanding shares of common stock of Auxilium for a per share consideration of $33.25 in a cash and stock transaction valued at about $2.6 bln.Termination of the waiting period satisfies a condition to the closing of the transaction.Completion of the transaction remains subject to approval by Auxilium stockholders and certain other customary closing conditions.  Full Article

Endo International PLC raises FY 2014 guidance
Wednesday, 5 Nov 2014 07:03am EST 

Endo International PLC:Raises FY 2014 expected revenues to range from $2.80 billion to $2.88 billion and raises expected FY 2014 adjusted diluted EPS to range from $4.10 to $4.25.Expects FY 2014 reported diluted (GAAP) loss per share to be in range from $3.95 to $3.80.FY 2014 revenue of $2.81 billion and EPS of $4.09 - Thomson Reuters I/B/E/S.  Full Article

Endo International PLC To acquire Auxilium Pharmaceuticals Inc
Thursday, 9 Oct 2014 06:30am EDT 

Endo International PLC and Auxilium Pharmaceuticals Inc:Have entered into a definitive agreement under which Endo will acquire all of the outstanding shares of common stock of Auxilium for a per share consideration of $33.25 in a cash and stock transaction.The boards of directors of both companies have unanimously approved the transaction, which is valued at $2.6 billion, including the repayment and assumption of debt.The per share consideration represents a premium of 55 pct to Auxilium's closing price on Sept. 16.The transaction is expected to close in the first half of 2015.Citi served as financial advisor to Endo, Lazard provided an independent fairness opinion and Sullivan & Cromwell LLP served as legal advisor.Deutsche Bank served as lead financial advisor, Morgan Stanley served as financial advisor and Willkie Farr & Gallagher LLP and Morgan, Lewis & Bockius served as legal advisors to Auxilium.  Full Article

Endo reaches master settlement agreements to resolve substantially all remaining AMS Mesh Litigation Claims
Tuesday, 30 Sep 2014 05:08pm EDT 

Endo International PLC:Reaches master settlement agreements with several of remaining plaintiffs' law firms to resolve claims relating to vaginal mesh products sold by Endo's AMS subsidiary.Says agreements, were entered into solely by way of compromise and settlement and are not in any way an admission of liability or fault.The settlements are expected to resolve substantially all of AMS U.S. vaginal mesh-related claims.  Full Article

Endo International PLC comments on Auxilium Pharmaceutical's rejection of acquisition proposal
Monday, 22 Sep 2014 08:49am EDT 

Endo International PLC:Commented on Auxilium Pharmaceuticals, Inc.'s decision not to accept its proposal to acquire Auxilium for a per share consideration of $28.10 in a cash and stock transaction valued at $2.2 bln.Citi is serving as a financial advisor to Endo, and Sullivan & Cromwell LLP is serving as its legal advisor.  Full Article

Endo International PLC delivers proposal to acquire Auxilium Pharmaceuticals
Tuesday, 16 Sep 2014 04:45pm EDT 

Endo International PLC:Says it has delivered a proposal to acquire all of the outstanding shares of Auxilium Pharmaceuticals, Inc. for a per share consideration of $28.10 in a cash and stock transaction valued at $2.2 bln.Endo's proposal represents a premium of 31 pct to Auxilium's closing price on Sept. 16 and a 40 pct premium to the average closing price of Auxilium shares for the previous 30 days.Under the terms of the proposal, consideration would include an about equal mix of cash and Endo stock.Endo intends to fund the transaction through a combination of existing cash on hand and debt financing.  Full Article

Endo International PLC announces launch of Authorized Generic of FORTESTA Gel
Monday, 8 Sep 2014 07:30am EDT 

Endo International PLC:Says it has introduced the first and only generic 2 pct topical testosterone gel, an authorized generic of FORTESTA Gel (testosterone gel) CIII.Says FORTESTA Gel and its Authorized Generic version are the first and only 2 pct testosterone gels approved by the U.S. Food and Drug Administration to treat adult males diagnosed with hypogonadism.Says Authorized Generic product, distributed by Qualitest and promoted by Endo Pharmaceuticals Inc., has product inventory which has shipped and is available.  Full Article

Search Stocks